Table 1. Ki-67 expression and viability relative to suspension according to clinical and biological parameters.
| KI-67 expression relative to suspension | Viability relative to suspension | ||||||
|---|---|---|---|---|---|---|---|
| Fold chango | N | T-test p value | % | N | T-test p value | ||
| Stage | A | 11D5±2.42 | 13 | 0.430 | 62.24±11.59 | 12 | 0.673 |
| B+C | 7.23±4.76 | 5 | 45.54±4.44 | 6 | |||
| CD38 expression | ≤30% | 9.70±2.46 | 13 | 0.767 | 54.81±9.95 | 14 | 0.222 |
| >30% | 10.75±4.85 | 5 | 63.19±10.01 | 4 | |||
| ZAP-70 expression | ≤20% | 12.13±3.34 | 10 | 0.315 | 53.29±10.56 | 12 | 0.325 |
| >20% | 7.32±2.34 | 8 | 63.44±11.98 | 6 | |||
| IGFiV status | mutated | 5.08±3.21 | 3 | 0.811 | 61.08±28.15 | 0.727 | |
| unmutated | 7.7432.95 | 10 | 65.78±13.26 | 9 | |||